RESTART C0168Z05 Rheumatoid Arthritis Study
Public ClinicalTrials.gov record NCT00714493. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 4, Multicenter, Open-Label, Assessor-Blinded Switch Study of the Efficacy and Safety of Infliximab (REMICADE) in Patients With Active Rheumatoid Arthritis Who Are Responding Inadequately to Etanercept (ENBREL) or Adalimumab (HUMIRA).
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the effectiveness of treatment in patients with active rheumatoid arthritis who are having an inadequate response to at least 3 months of treatment with etanercept or adalimumab in addition to methotrexate.
Study identification
- NCT ID
- NCT00714493
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 203 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2008 (Type not available)
- Primary completion
- Jan 2010 (Actual)
- Completion
- Jun 2010 (Actual)
- Last update posted
- Sep 12, 2013
2008 – 2010
United States locations
- U.S. sites
- 45
- U.S. states
- 24
- U.S. cities
- 45
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Huntsville | Alabama | — | — |
| Not listed | Paradise Valley | Arizona | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | Santa Monica | California | — | — |
| Not listed | Bridgeport | Connecticut | — | — |
| Not listed | Lewes | Delaware | — | — |
| Not listed | Boca Raton | Florida | — | — |
| Not listed | Palm Harbor | Florida | — | — |
| Not listed | Tamarac | Florida | — | — |
| Not listed | Vero Beach | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Moline | Illinois | — | — |
| Not listed | Springfield | Illinois | — | — |
| Not listed | Lexington | Kentucky | — | — |
| Not listed | Wheaton | Maryland | — | — |
| Not listed | Saint Clair Shores | Michigan | — | — |
| Not listed | Eagan | Minnesota | — | — |
| Not listed | Springfield | Missouri | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Berkeley Heights | New Jersey | — | — |
| Not listed | Freehold | New Jersey | — | — |
| Not listed | Albany | New York | — | — |
| Not listed | Syracuse | New York | — | — |
| Not listed | Chapel Hill | North Carolina | — | — |
| Not listed | Columbus | Ohio | — | — |
| Not listed | Mayfield | Ohio | — | — |
| Not listed | Middleburg Heights | Ohio | — | — |
| Not listed | Tulsa | Oklahoma | — | — |
| Not listed | Allentown | Pennsylvania | — | — |
| Not listed | Duncansville | Pennsylvania | — | — |
| Not listed | Wexford | Pennsylvania | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Greenville | South Carolina | — | — |
| Not listed | Jackson | Tennessee | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Amarillo | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Fort Worth | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Mesquite | Texas | — | — |
| Not listed | Temple | Texas | — | — |
| Not listed | Tyler | Texas | — | — |
| Not listed | Burke | Virginia | — | — |
| Not listed | Reston | Virginia | — | — |
| Not listed | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00714493, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 12, 2013 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00714493 live on ClinicalTrials.gov.